SCHEMBL759389

SCHEMBL759389

CC(C)C(=O)c1ccc2ccccc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.61
CES1 P23141 1/20 0.61
KDM4E B2RXH2 4/20 0.59
ALDH1A1 P00352 3/20 0.59
GAA P10253 2/20 0.59
DBH P09172 1/20 0.55
RECQL P46063 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.52
HPGD P15428 3/20 0.52
MEN1 O00255 1/20 0.52
EGFR P00533 1/20 0.52
TP53 P04637 1/20 0.52
CYP3A4 P08684 1/20 0.52
MAPT P10636 1/20 0.52
PKM P14618 1/20 0.52
ALOX15 P16050 1/20 0.52
ALOX12 P18054 1/20 0.52
JAK1 P23458 1/20 0.52
MAPK1 P28482 1/20 0.52
KMT2A Q03164 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16811768 0.94 ALDH1A1 (0.54) CES2CES1KDM4EALDH1A1GAA
SCHEMBL12418686 0.92 KDM4E (0.63) CES2CES1KDM4EALDH1A1GAA
SCHEMBL2599186 0.86 CES2 (0.59) CES2CES1KDM4EALDH1A1GAA
SCHEMBL15007511 0.86 CES2 (0.59) CES2CES1KDM4EALDH1A1GAA
SCHEMBL28100961 0.85 ALDH1A1 (0.67) CES2CES1KDM4EALDH1A1GAA
SCHEMBL10458095 0.85 KDM4E (0.52) CES2CES1KDM4EALDH1A1GAA
SCHEMBL9117029 0.85 CES2 (0.57) CES2CES1KDM4EALDH1A1GAA
SCHEMBL5130655 0.85 CES2 (0.57) CES2CES1KDM4EALDH1A1GAA
SCHEMBL2951738 0.85 ALDH1A1 (0.62) CES2CES1KDM4EALDH1A1GAA
SCHEMBL6008182 0.85 CES2 (0.57) CES2CES1KDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119504333-A Preparation method and application of 2-methyl-6-alkyl naphthalene 煤炭科学技术研究院有限公司 2025-02-25 CN disclosed
CN-222056389-U 2-Methyl-6-propionyl naphthalene purification refining device 品恩赢创(苏州)新材料科技有限公司 2024-11-26 CN disclosed
CN-222056389-U 2-Methyl-6-propionyl naphthalene purification refining device 品恩赢创(苏州)新材料科技有限公司 2024-11-26 CN disclosed
CN-118307394-A Purification method of crude product of 2-methyl-6-propionylnaphthalene 品恩赢创(苏州)新材料科技有限公司 2024-07-09 CN disclosed
US-20240207355-A1 PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG L-Base Co., Ltd. (KR) 2024-06-27 US disclosed
EP-3445812-B1 REGIOSELECTIVELY SUBSTITUTED CELLULOSE ESTERS AND FILMS MADE THEREFROM EASTMAN CHEM CO (US) 2023-10-25 EP disclosed
US-20230235093-A1 REGIOSELECTIVELY SUBSTITUTED CELLULOSE ESTERS AND FILMS MADE THEREFROM EASTMAN CHEMICAL COMPANY (US) 2023-07-27 US disclosed
US-20230159587-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER L-Base Co., Ltd. (KR) 2023-05-25 US disclosed
US-20230159587-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER L-Base Co., Ltd. (KR) 2023-05-25 US disclosed
US-11643477-B2 Regioselectively substituted cellulose esters and films made therefrom EASTMAN CHEMICAL COMPANY (US) 2023-05-09 US disclosed
US-7169760-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2007-01-30 US disclosed
CN-1817843-A Production of 2-alkyl-6-acyl-naphthaline HUADONG SCIENCE AND TECHNOLOGY (CN) 2006-08-16 CN disclosed
WO-2006016708-A1 FUNGICIDAL COMPOSITION CONTAINING ACID AMIDE DERIVATIVE ISHIHARA SANGYO KAISHA, LTD. (JP) 2006-02-16 WO disclosed
CN-1142928-C Synthesis and use of retinoid compounds having negative hormone and/or antagonist activity �ո��� 2004-03-24 CN disclosed
CN-1121379-C Synthesis and use of retinoid having negative hormone and/or antagonist activity ALLERGAN CO (US) 2003-09-17 CN disclosed
CN-1268130-A Synthesis and use of retinol derivative compounds having negative hormone and/or antagonist activity ALLERGAN SALES INC (US) 2000-09-27 CN disclosed
CN-1209802-A Synthesis and use of retinoid having negative hormone and/or antagonist activity ALLERGAN CO (US) 1999-03-03 CN disclosed
EP-0273647-B1 COUMARAN DERIVATIVES, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1992-03-11 EP disclosed
US-4857516-A Coumaran derivatives and their pharmaceutical use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1989-08-15 US disclosed
EP-0273647-A1 Coumaran derivatives, their production and use Takeda Chemical Industries, Ltd. (JP) 1988-07-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159587-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER VIP, QPCT, TPT1 CES2 4869/4885CES1 3055/4885KDM4E 4144/4885
US-20240207355-A1 PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG ALPG, SLC11A2, SGTA CES2 4879/4885CES1 4726/4885KDM4E 3119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.